AVIR · CIK 0001593899
What Atea Pharmaceuticals, Inc. told the SEC could break it.
Atea's disclosures center on a fragile, China-concentrated supply chain behind a pre-revenue drug program. It relies on a single China-based supplier for ruzasvir's active ingredient and sources all the regulatory starting materials for both ruzasvir and bemnifosbuvir from China — with no long-term agreements and no alternative sources — and that dependence also exposes it to U.S. tariffs on Chinese pharmaceutical inputs that could raise costs. Underpinning it all, Atea has never earned product revenue, posted a $158.3M net loss in 2025 against a $522.6M accumulated deficit, and depends on the success of its hepatitis C program and equity financing to keep going.
3 self-disclosed vulnerabilities, pulled from its own filings, each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- sole China supplier for ruzasvir API; all starting materials from China; no long-term agreementshigh
Atea relies on a single China-based supplier for ruzasvir's active pharmaceutical ingredient and sources all regulatory starting materials for both ruzasvir and bemnifosbuvir from China, with no long-term supply agreements and no alternative sources — a concentrated, fragile supply chain.
“For ruzasvir, we have a sole supplier located in China for our active pharmaceutical ingredient, and for both ruzasvir and bemnifosbuvir, all suppliers of the regulatory starting 84 materials for the respective manufacturing processes are located in China. We do not have long-term supply agreements with any of our component suppliers.”
Liquidity & debt
- pre-revenue with $522.6M accumulated deficitmedium
Atea has never generated product revenue, posted a $158.3M net loss in 2025 and a $522.6M accumulated deficit (with $301.8M cash), depending on its HCV program's success and equity financing (a $200M Jefferies ATM) to continue.
“As of December 31, 2025, we had an accumulated deficit of $522.6 million. We have not commercialized any products and have never generated any revenue from product sales.”
SEC filing →As of 2026
Regulatory & policy
- U.S. tariffs on China-sourced pharmaceutical inputsmedium
Because Atea's API and starting materials come from China, U.S. tariffs and shifting trade policy (some 2025 tariffs were challenged but may be reimposed) could raise costs and force operational changes.
“tariffs enacted by the US federal government in 2025 have been subject to successful legal challenge, but it remains unclear whether and to whom those tariffs may be refunded, and the US federal government may attempt to impose new or similar tariffs under alternative statutory mechanisms.”
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch